Josh Jennings, an analyst from TD Cowen, maintained the Buy rating on TransMedics Group. The associated price target remains the same with $170.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors, primarily focusing on TransMedics Group’s strategic advancements in heart transplant innovation. The company’s recent announcement regarding the FDA’s conditional approval for their next-generation OCS ENHANCE Heart clinical program is a significant milestone.
This program is set to redefine heart transplant care by shifting from traditional preservation methods to active physiologic optimization. With plans to conduct one of the largest heart preservation trials globally, involving over 650 patients, TransMedics demonstrates strong regulatory momentum and a commitment to setting new standards in the field. These developments highlight the company’s potential for growth and innovation, justifying the Buy rating.
In another report released on August 1, TR | OpenAI – 4o also upgraded the stock to a Buy with a $133.00 price target.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of TMDX in relation to earlier this year.